v3.26.1
Revenue (Tables)
 3 Months Ended
Mar. 31, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
Three Months Ended March 31,
 20262025
Net product revenue$18,453 $11,601 
Collaboration and other revenue
1,346 1,127 
Revenue$19,799 $12,729 
The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the three months ended March 31, 2026 and 2025:
Three Months Ended March 31,
 20262025
U.S.
Outside U.S.Total
U.S.
Outside U.S.Total
Cardiometabolic Health:
Mounjaro$4,232 $4,430 $8,662 $2,656 $1,186 $3,842 
Zepbound(1)
4,134 26 4,160 2,305 7 2,312 
Jardiance(2)
512 602 1,114 310 705 1,014 
Trulicity600 318 919 771 325 1,095 
Other cardiometabolic health446 460 905 535 410 945 
Total cardiometabolic health9,924 5,836 15,760 6,577 2,631 9,208 
Oncology:
Verzenio706 596 1,302 658 501 1,159 
Other oncology522 444 966 388 400 789 
Total oncology1,228 1,040 2,268 1,046 902 1,948 
Immunology:
Taltz417 315 733 477 285 762 
Other immunology202 269 470 102 225 326 
Total immunology619 584 1,203 578 510 1,088 
Neuroscience293 89 382 189 83 272 
Other
56 130 187 100 113 213 
Revenue$12,119 $7,680 $19,799 $8,489 $4,239 $12,729 
(1) Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the U.S.
(2) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.
The following table summarizes revenue by geographical area:
Three Months Ended March 31,
20262025
Revenue(1):
U.S.$12,119 $8,489 
Europe3,646 2,389 
China693 451 
Japan571 402 
Rest of world2,771 997 
Revenue$19,799 $12,729 
(1) Revenue is attributed to the countries based on the location of the customer or other party.